Firms Await Brazilian Regulator’s Decision On Allowing ‘Skinny Labels’ For Generics
Regulator ANVISA Began Efforts Allowing Skinny Labels Late Last Year
Executive Summary
The Brazilian medicines regulator, ANVISA, is considering whether to allow generic drug labeling to omit indications of the originator product that are still under patent. "Skinny labels" also figure in an ongoing court case involving Boehringer Ingelheim's Ofev (nintedanib).
You may also be interested in...
Dissent In Parliament As Commission Claims EU Pharma Revision Will Improve Competitiveness and Access
Proposals on regulatory data protection and transferable exclusivity vouchers to encourage antimicrobial R&D have received mixed reactions from the parliament’s rapporteurs for the draft legislation.
New Swiss Database To Cut Costs Of GMP/GDP Certification
A new database being set up in Switzerland is expected to improve the exchange of GMP and GDP information between the regulatory authorities and pharmaceutical companies and offer free access to electronic certificates.
Lawmakers Finally Kick Off Debate On EU Pharma Overhaul
The late delivery of the “pharmaceutical package” leaves little time for the legislative process to take shape before European Parliament elections are held in June next year.